Researchers at the University of California, Davis, have developed compounds for the potential prevention and treatment of mitochondrial dysfunction disorders.
Many neurological disorders, including some degenerative diseases, result from insufficient mitochondrial function in neural cells. One strategy to prevent or treat these disorders is to increase the mitochondrial biogenesis to compensate for the impaired function. Currently, there are no FDA-approved drug for the prevention or good treatment of many of these neurological diseases. Therefore, there is a need for therapies of increasing mitochondrial mass, number and/or overall neural function.
Researchers at the University of California, Davis, have developed agents for increasing mitochondrial biogenesis in neural cells. The researchers have successfully tested the treatments in vitro in human fibroblast cells and in vivo mouse models of Parkinson’s disease and optic neuropathy to dose-dependently increase mitochondrial proteins. When used in therapeutic combination, the agents produced a potentiated effect.
|Patent Cooperation Treaty||Reference for National Filings||2019143560A9||07/25/2019||2018-315|
Mitochondrial Biogenesis, Neural Cells, Mitochondrial Dysfunction Disorders, Mitochondrial Proteins, Mitochondria